The SmPC highlights several important safety considerations
Bioavailability for peptides through the sublingual route is generally in the 3-10% range, comparable to nasal delivery
"This [Wegovy pill approval] win is symbolically very important for Novo, after a series of disappointments with data and financial performance," she added
[62] Viking Therapeutics (VK2735) VK2735 is a GLP1R/GIPR dual agonist, with a half-life of around 170-250 hours, undergoing both oral and subcutaneous injection clinical trials
You can also take a look at our comprehensive list of employers who typically offer coverage for these anti-obesity medications
At first glance, it looks like the patent was unnecessary since semaglutide was already protected by data exclusivity, and both were ending in early 2026